To treat? Or not to treat? – that was the question in the Federal Circuit decision in the case of INO Therapeutics LLC v. Praxair Distribution Inc.1 (2018-1019). INO provides an interesting development in the patent...more
As the path to legality of cannabis and cannabis-related products progresses, the formerly illegal world of marijuana now confronts legal principles beyond law enforcement. And the patent laws are no exception. On April 17,...more
On April 13, 2018, in a split decision, the Federal Circuit held that Vanda Pharmaceuticals Inc.’s method of treatment claims are directed to patent-eligible subject matter under step one of the Mayo two-step test. Vanda...more
On August 4, 2017, a pair of decisions reaffirmed that claimed methods which apply routine and conventional techniques to a law of nature are invalid and do not satisfy the “inventive concept” step of the patent eligibility...more